Comparative Pharmacology
Head-to-head clinical analysis: MULTAQ versus PRONESTYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MULTAQ versus PRONESTYL.
MULTAQ vs PRONESTYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dronedarone is a multichannel blocker that inhibits potassium currents (IKr, IKs, IK-ACh), sodium current (INa), and L-type calcium current (ICaL), and has antiadrenergic properties via noncompetitive blockade of beta-adrenergic receptors.
Class IA antiarrhythmic; blocks sodium channels, decreases phase 0 upstroke velocity, prolongs action potential duration, and increases effective refractory period.
400 mg orally twice daily with morning and evening meals.
For life-threatening ventricular arrhythmias: loading dose of 100 mg IV over 5 minutes, repeated every 5 minutes as needed up to a total of 1 g. Maintenance: continuous IV infusion of 1-4 mg/min. Oral: 50 mg/kg/day in divided doses every 3-6 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) after oral administration, allowing for twice-daily dosing.
3-5 hours in patients with normal renal function; prolonged to 10-20 hours in renal impairment. Clinical context: Requires dosing every 3-4 hours to maintain therapeutic levels; sustained-release formulations allow Q6-8h dosing.
Primarily fecal (84%) after biliary excretion; renal excretion accounts for <6% as unchanged drug and metabolites.
Renal excretion accounts for approximately 50-60% of procainamide elimination as unchanged drug, with an additional 10-30% as the active metabolite N-acetylprocainamide (NAPA). Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Antiarrhythmic
Antiarrhythmic